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DNA methylat ion i s  one of  the main epigenet ic 
mechanisms, known to be operative in mammals. Extensive 
evidence has highlighted its pivotal role in several 
fundamental biological processes including organogenesis, 
X-chromosome inactivation and genomic imprinting (1). 
Although our understanding of how DNA methylation 
impacts on gene transcription and cellular function remains 
incomplete, it is clear that DNA methylation plays an 
important role in defining cell and tissue specific cellular 
function (2,3). Increasing evidence suggests that altered 
DNA methylation can contribute to either the development 
and/or persistence of many human diseases. Importantly, 
what makes epigenetic mechanisms a particularly 
attractive concept when it comes to investigating disease 
pathogenesis of modern, multi-factorial/complex diseases 
is their responsiveness to environmental factors (4). The 
incidence of inflammatory bowel diseases (IBDs) such as 
Crohn’s Disease (CD) and ulcerative colitis (UC) has been 
increasing dramatically in recent decades with disease onset 
shifting to younger age groups and disease phenotypes 
becoming more aggressive (5). Assuming an overall stable 
human genome combined with well documented links 
to several environmental factors (e.g., western lifestyle) 
epigenetics may provide a missing mechanistic link between 
environmental changes and stable alterations in cellular 
function either causing chronic relapsing gut inflammation 
and/or contributing to its persistence (6). However, despite 
the plausible concept, providing supportive evidence has 
proven to be difficult and as a result high quality studies 
remain scarce (7,8). 
In the June 2019 edition of Gastroenterology, Somineni 
and colleagues report on the results of a study investigating 
blood-derive DNA methylation signatures in children 
diagnosed with CD and their correlation with disease 
severity as well as intestinal inflammation (9). The group 
of investigators performed genome wide DNA methylation 
analyses (using Illumina EPIC arrays) of whole blood 
derived DNA samples obtained from 164 treatment naïve 
CD patients at the point of diagnosis and 74 matched 
non-IBD controls. Longitudinal follow-up samples were 
obtained from all CD patients during the course of disease 
between 1–3 years. In addition to DNA methylation, 
genotyping was performed on all samples and detailed 
clinical follow-up data was prospectively recorded allowing 
the authors to correlate epigenetic signatures with disease 
phenotype and outcome. 
Comparative methylation analyses revealed a total of 
1,189 CpGs that were found to be differentially methylated 
in CD patients at diagnosis compared to non-IBD controls. 
Moreover, methylation changes strongly correlated with 
systemic inflammation, i.e., serum CRP levels. Interestingly, 
the vast majority of methylation changes (except from 
Editorial Commentary
The value of blood derived DNA methylation signatures in 
advancing our understanding of Crohn’s Disease pathogenesis
Matthias Zilbauer1,2,3
1Department of Paediatrics, University of Cambridge, Cambridge, UK; 2Department of Paediatric Gastroenterology, Hepatology and Nutrition, 
Cambridge University Hospitals, Cambridge, UK; 3Wellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, 
Cambridge, UK
Correspondence to: Prof. Matthias Zilbauer, MD, PhD, MA, MRCPCH. Department of Paediatrics, University of Cambridge, Cambridge, UK. 
Email: mz304@cam.ac.uk. 
Provenance: This is an invited article commissioned by our Guest Section Editor Dr. Li Min [Assistant Professor, Department of Gastroenterology, 
Beijing Friendship Hospital (National Clinical Research Center of Digestive Disease), Capital Medical University, Beijing, China].
Comment on: Somineni HK, Venkateswaran S, Kilaru V, et al. Blood-Derived DNA Methylation Signatures of Crohn's Disease and Severity of 
Intestinal Inflammation. Gastroenterology 2019;156:2254-65.e3.
Received: 14 July 2019; Accepted: 14 August 2019; Published: 20 August 2019.
doi: 10.21037/tgh.2019.08.07
View this article at: http://dx.doi.org/10.21037/tgh.2019.08.07
Page 2 of 3 Translational Gastroenterology and Hepatology, 2019
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2019;4:60 | http://dx.doi.org/10.21037/tgh.2019.08.07
3 CpGs) disappeared in longitudinal samples, in which 
CRP levels were also found to be lower. The authors 
conclude that their findings suggest disease associated 
DNA methylation changes are likely to be a result of 
inflammation rather than a causing factor. Therefore, these 
changes are less likely to contribute to disease development 
or progression. 
So, to what extend do these results provide evidence 
against the hypothesis that epigenetic alterations in disease 
relevant cell types are involved in either causing and/or 
maintaining chronic intestinal inflammation in IBD? 
In order to answer this question, we must take a critical 
view on the strengths and limitations of this study. Starting 
with the former, this work has numerous advantages making 
generated results highly valuable for the field. Major 
strengths include, the prospective recruitment of a large 
paediatric CD patient cohort at diagnosis (i.e., treatment 
naïve), documentation of long-term clinical follow-up as 
well as the availability of longitudinal samples. Additionally, 
performing epigenetic studies in paediatric patients, 
including recruitment of age matched non-disease controls 
has major advantages as the presence of co-morbidity and 
the potentially confounding impact of other environmental 
factors are limited. Lastly, the fact that this study recruited 
patients from multiple centres across the US further adds to 
its value. 
Despite the numerous advantages, there is one critical 
factor and major limitation that needs to be considered 
when interpreting the findings of this study: DNA 
methylation signatures were derived from mixed cell tissue 
samples (i.e., peripheral blood) which vary in their cellular 
composition according to the presence or absence of 
systemic inflammation. 
Hence, the main question that arsis is whether observed 
CD associated DNA methylation changes represent cell 
type specific epigenetic alterations or are the result of 
profiling different proportions of circulating immune cells, 
which all have unique methylation signatures (10). Whilst 
the former is impossible to proof given the study design, 
there are a number of findings that point towards a likely 
effect of cell composition on DNA methylation changes. 
Indeed, the authors demonstrate clear differences in cell 
composition of blood samples obtained from CD patients 
at diagnosis compared to controls (Figure S2). These 
differences largely disappear in follow-up samples and with-
it the vast majority of disease associated DNA methylation 
changes. Although the authors adjust for estimated cell 
subset proportions (estimates based on DNA methylation 
signatures) (11) as covariates when performing differential 
DNA methylation analysis, this approach cannot completely 
exclude a confounding effect of cell composition. Hence, 
the finding of CD associated DNA methylation changes at 
diagnosis reverting to being indistinguishable from controls 
at follow-up must be interpreted with caution. In this 
respect it is important to note that once fully established 
(e.g., in differentiated cells), DNA methylation is a highly 
stable epigenetic mark and hence it would be surprising if 
reported large-scale methylation changes are reversible in a 
relatively short period of time (i.e., 1–3 years). Although the 
authors’ conclusion that transient epigenetic changes are 
unlikely to play a major role in contributing to the chronic 
relapsing nature of IBD is correct, reported findings do not 
exclude their presence in individual cell subsets. 
Indeed, this represents another major limitation 
associated with performing epigenetic profiling on mixed 
cell tissue samples, that is the inability to identify disease 
associated alterations effecting specific cell types. This 
makes it impossible to investigate potential functional 
implications. Whilst correlating DNA methylation 
changes with transcriptional profiles appears a reasonable 
approach, in the study presented, transcriptional signatures 
were also derived from whole blood samples and hence 
the confounding impact of varying cellular composition 
equally applies. One may expect immune related pathways 
to be enriched if transcriptional profiles of samples with 
significant differences in immune cell composition are being 
compared.
Nevertheless, even if disease associated methylation 
changes are the result of changes in cell composition, they 
may still be of value as biomarkers provided they correlate 
with clinical parameters of interest. However, unfortunately 
the authors did not observe a correlation between DNA 
methylation and specific disease phonotype and/or disease 
progression thereby limiting the potential value of whole 
blood derived DNA methylation signatures as clinical 
biomarkers in paediatric CD. 
The concept of DNA methylation mediating genetic 
risk of CD is highly plausible and the study performs 
elegant analyses using a Mendelian randomization approach 
that benefits from the availability of genotype data for 
all patients. Identification of CD associated methylation 
changes at 3 CpGs, which showed significant causal 
associations and did not change during the course of disease 
provide promising evidence in support of this hypothesis 
despite the limited statistical power. Future studies 
particularly those performing single cell transcriptional 
Page 3 of 3Translational Gastroenterology and Hepatology, 2019
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2019;4:60 | http://dx.doi.org/10.21037/tgh.2019.08.07
profiling are likely to shed further light on this concept.   
In summary, the study by Somineni and colleagues 
provides an important contribution to the field particularly 
when interpreted in the context of its specific strengths 
and limitations. Importantly, whilst highlighting many 
challenges associated with performing epi-genome wide 
association studies, results do not oppose the main concept 
of epigenetic mechanisms playing a crucial role in disease 




Conflicts of Interest: The author has no conflicts of interest to 
declare.
Ethical Statement: The author is accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.
References
1. Smith ZD, Meissner A. DNA methylation: roles in 
mammalian development. Nat Rev Genet 2013;14:204-20.
2. Illingworth R, Kerr A, Desousa D, et al. A novel CpG 
island set identifies tissue-specific methylation at 
developmental gene loci. PLoS Biol 2008;6:e22.
3. Schubeler D. Function and information content of DNA 
methylation. Nature 2015;517:321-6.
4. Paul B, Barnes S, Demark-Wahnefried W, et al. Influences 
of diet and the gut microbiome on epigenetic modulation 
in cancer and other diseases. Clin Epigenetics 2015;7:112.
5. Van Limbergen J, Russell RK, Drummond HE, et al. 
Definition of phenotypic characteristics of childhood-
onset inflammatory bowel disease. Gastroenterology 
2008;135:1114-22.
6. Jenke AC, Zilbauer M. Epigenetics in inflammatory bowel 
disease. Curr Opin Gastroenterol 2012;28:577-84.
7. Callaway E. Epigenomics starts to make its mark. Nature 
2014;508:22.
8. Whyte JM, Ellis JJ, Brown MA, et al. Best practices in 
DNA methylation: lessons from inflammatory bowel 
disease, psoriasis and ankylosing spondylitis. Arthritis Res 
Ther 2019;21:133.
9. Somineni HK, Venkateswaran S, Kilaru V, et al. Blood-
Derived DNA Methylation Signatures of Crohn's Disease 
and Severity of Intestinal Inflammation. Gastroenterology 
2019;156:2254-65.e3.
10. Zilbauer M, Rayner TF, Clark C, et al. Genome-wide 
methylation analyses of primary human leukocyte subsets 
identifies functionally important cell-type-specific 
hypomethylated regions. Blood 2013;122:e52-60.
11. Houseman EA, Accomando WP, Koestler DC, et al. DNA 
methylation arrays as surrogate measures of cell mixture 
distribution. BMC Bioinformatics 2012;13:86.
doi: 10.21037/tgh.2019.08.07
Cite this article as: Zilbauer M. The value of blood derived 
DNA methylation signatures in advancing our understanding 
of Crohn’s Disease pathogenesis. Transl Gastroenterol Hepatol 
2019;4:60. 
